These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23921688)

  • 1. Bleeding associated with acquired factor V inhibitor in a patient on warfarin treated successfully with prednisolone.
    Khalafallah A; Grabek J; Hayes R; Mohamed M
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23921688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High-titer idiopathic acquired factor V inhibitor patient showing decreased activities of multiple coagulation factors].
    Shimizu I; Ichikawa N; Yotsumoto M; Sumi M; Ueno M; Kobayashi H
    Rinsho Ketsueki; 2008 Jun; 49(6):413-6. PubMed ID: 18646609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe bleeding caused by an inhibitor to coagulation factor V: a case report.
    Smid WM; de Wolf JT; Nijland JH; Bom VJ; van der Meer J
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):133-7. PubMed ID: 8180333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors.
    Nakata K; Ueda S; Matsunaga H; Mima F; Ueda H; Yoshioka A; Kaneko S; Maruo K; Morris S; Yonemoto S; Hayashi D; Fujii N; Narahara H; Inui Y; Kawata S
    Intern Med; 2018 Feb; 57(3):393-397. PubMed ID: 29093398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired factor V inhibitor associated with life-threatening bleeding and a mixing test result that indicated coagulation factor deficiency.
    Ashizawa M; Kimura S; Wada H; Sakamoto K; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Kako S; Yamazaki R; Oshima K; Matsuura K; Ohmori T; Madoiwa S; Nishida J; Mimuro J; Tabei K; Sakata Y; Kanda Y
    Hematology; 2013 Sep; 18(5):300-4. PubMed ID: 23683688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy.
    Sarode R; Rawal A; Lee R; Shen YM; Frenkel EP
    Br J Haematol; 2006 Mar; 132(5):604-7. PubMed ID: 16445834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers.
    Endo H; Kawauchi K; Tomimatsu M; Iga D; Ogasawara T; Yasuyama M; Saito T; Otsuka K; Aiba M
    Intern Med; 2007; 46(9):621-5. PubMed ID: 17473502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired factor V inhibitor complicating warfarin therapy.
    Gartrell B
    Am J Hematol; 2011 Aug; 86(8):710-2. PubMed ID: 21761437
    [No Abstract]   [Full Text] [Related]  

  • 9. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired Factor V Inhibitor with Hemorrhagic Symptoms after Prasugrel Hydrochloride Treatment.
    Sakatoku K; Takakuwa T; Miura A; Araki T; Fujitani Y; Yamamura R
    Acta Haematol; 2020; 143(5):478-480. PubMed ID: 31522179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate.
    Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC
    World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding.
    Stewart WS; Pettit H
    Am J Emerg Med; 2013 Aug; 31(8):1251-4. PubMed ID: 23763937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocolized use of Factor Eight Inhibitor Bypassing Activity (FEIBA) for the reversal of warfarin induced coagulopathy.
    Htet NN; Barounis D; Knight C; Umunna BP; Hormese M; Lovell E
    Am J Emerg Med; 2020 Mar; 38(3):539-544. PubMed ID: 31176578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose.
    Yasaka M; Oomura M; Ikeno K; Naritomi H; Minematsu K
    Ann Hematol; 2003 Feb; 82(2):121-3. PubMed ID: 12601493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 75-year-old woman with acquired haemophilia disguised by warfarin treatment.
    Lawless S; Benson G
    BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26443092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life-threatening bleeding in a patient with a lupus inhibitor and probable acquired factor VII deficiency.
    Lim S; Zuha R; Burt T; Chacko J; Scott R; Mainwaring CJ
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):667-71. PubMed ID: 17102654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new kid on the block: Outcomes with Kcentra 1 year after approval.
    Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
    J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Management of Acquired Factor V Inhibitor by Monitoring Factor V Activity, Antigen, and Inhibitor Values during Immunosuppressive Therapy.
    Mihara M; Ogawa Y; Nagasaka M; Kobayashi N; Shimizu H; Shinozawa K; Fukutake K; Inoue M; Murakami M; Handa H
    Acta Haematol; 2020; 143(5):486-490. PubMed ID: 31563916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Factor V Inhibitors in a Patient with End-stage Renal Disease.
    Kitazawa A; Misawa H; Nagahori K; Koda R; Yoshino A; Kawamoto S; Takeda T
    Intern Med; 2016; 55(23):3505-3509. PubMed ID: 27904118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recurrence of acquired factor V inhibitor after four years of remission].
    Akashi N; Ogawa Y; Yanagisawa K; Osaki Y; Shimizu H; Ishizaki T; Inoue M; Murakami M; Souri M; Ichinose A; Handa H
    Rinsho Ketsueki; 2019; 60(1):46-50. PubMed ID: 30726824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.